GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Gross Profit

Anavex Life Sciences (Anavex Life Sciences) Gross Profit : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences Gross Profit?

Anavex Life Sciences's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. Anavex Life Sciences's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Anavex Life Sciences's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. Anavex Life Sciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Anavex Life Sciences's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Anavex Life Sciences had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Anavex Life Sciences Gross Profit Historical Data

The historical data trend for Anavex Life Sciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Gross Profit Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anavex Life Sciences's Gross Profit

For the Biotechnology subindustry, Anavex Life Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Gross Profit falls into.



Anavex Life Sciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Anavex Life Sciences's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as

Gross Profit (A: Sep. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Anavex Life Sciences's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Anavex Life Sciences's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Anavex Life Sciences  (NAS:AVXL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Anavex Life Sciences had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Anavex Life Sciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (Anavex Life Sciences) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
Christopher U Missling director, officer: President, CEO, CFO, Treasurer, other: Secretary 61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos 10 percent owner 14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma director 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o. director REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch officer: PFO & Treasurer 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden director PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas director FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh director, officer: Executive Director
John Robert Chisholm director 16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry director 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley director 14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach director, officer: President CEO CFO 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers director 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052